This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
Author(s):

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

1 Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA; 2 Neuroscience Education Institute, Lakewood Ranch, FL, USA; 3 Alkermes, Inc., Waltham, MA, USA; 4 Optum, Inc., Eden Prairie, MN, USA; 5 Fortitude Behavioral Health, Baltimore, MD, USA; 6 Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA

Content available until 11/07/2026